AbbVie: Competitor Pricing, Humira Formulary Placement Will Dictate US Biosimilars Impact

 
• By Joseph Haas

Now just months away from the first US Humira biosimilar launch, analysts are asking AbbVie for specifics on expected revenue erosion. CEO Gonzalez said AbbVie aims for 90% formulary coverage in 2023.

Revenue report
AbbVie continues to work to maintain US access to Humira after biosimilars reach market • Source: Shutterstock

More from Earnings

More from Business